Review article

Rod metabolic demand drives progression in retinopathies

Michael K. Lin a, Soo Hyun Kim b, Lijuan Zhang c, Yi-Ting Tsai c, Stephen H. Tsang c, d, *  

a College of Physicians & Surgeons, Columbia University, New York, NY, USA  
b Columbia College, Columbia University, New York, NY, USA  
c Bernard & Shiree Brown Glaucoma Laboratory and Barbara & Donald Jonas Stem Cell Laboratory, Department of Ophthalmology, Columbia University, New York, NY, USA  
d Department of Pathology and Cell Biology and Institute of Human Nutrition, Columbia University, New York, NY, USA

A R T I C L E   I N F O

Article history:  
Received 10 May 2015  
Accepted 30 June 2015  
Available online 25 August 2015

Keywords:  
diabetic retinopathy  
macular degeneration  
metabolism  
retinitis pigmentosa  
SIRT6

A B S T R A C T

Various factors are thought to cause the development and progression of disease in macular degeneration, diabetic retinopathy, and retinitis pigmentosa. Some of the deleterious processes include oxidative stress, hypoxia, metabolic derangement, genetics, and vasculopathy. In this review, we present a unified theory for the pathophysiology of several retinopathies based on the unique and intense metabolism of rod photoreceptors.

Copyright © 2015, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights reserved.

1. Introduction

Rod photoreceptors consume more energy in darkness than in light.1 Unlike most other neurons, rods do not fire action potentials. Rather, in darkness they exhibit a continuous depolarized state of the rod membrane potential that allows constant neurotransmitter release to activate second-order neurons in the visual pathway.2 The “dark current” is maintained by cyclic-nucleotide-gated (CNG) channels that allow inward flow of cations, approximately 80% Na+ and 15% Ca2+. The Ca2+ influx is balanced by a Na+/Ca2+–K+ exchanger that exchanges four Na+ inward for one Ca2+ and one K+ outward, and the large Na+ influx is balanced by a Na+/K+ ATPase at the inner segment.3 Rods consume up to four times as much adenosine triphosphate (ATP) in darkness as that in light to support the high energy demand of these transmitters; one ATP is consumed per Ca2+ exported and one ATP is consumed per three Na+ exported.4 Photoexcitation closes the CNG channel, preventing influx of Na+ and Ca2+ and causing hyperpolarization across the rod membrane, which reduces neurotransmitter release. For reviews of phototransduction, see the works of Yau and Hardie3 and Fain et al.4 Briefly, in rod phototransduction, light activates rhodopsin, which activates the G protein transducin, which in turn activates phosphodiesterase, which hydrolyzes cyclic guanosine monophosphate (cGMP) to guanosine monophosphate (GMP).5–9 Removal of cGMP from the CNG channel causes channel closure and prevents the influx of cations.3,4

The high energy demand for maintaining the “dark current” causes rods to consume the highest amount of energy among all cell types in the body.10–12 A large amount of ATP and Nicotinamide adenine dinucleotide phosphate (NADPH) are needed for recovery of cGMP from photoexcitation and its resynthesis in darkness.13 In darkness, to meet the ATP demands of ion transporters, rods use large amounts of O2 and glucose that are metabolized by both glycolysis and oxidative phosphorylation (Fig. 1).13,14 In light, however, consumption of O2 by rods was shown to decrease by approximately 30% in macaques and approximately 50–70% in cats,10–12 indicating a marked reduction in oxidative phosphorylation in light compared with that in darkness (Fig. 1). In light, there is increased anabolic activity14; mRNA levels are increased four to 10 times,15,16 and outer segments appear to follow a circadian pattern, in which discs are shed more at the onset of light in a 12-hour light–dark cycle irrespective of whether the lights are turned on or not, which is accompanied by an increase in outer segment renewal,17,18 presumably fueled by increased lipid and protein production.

Conflicts of interest: The authors report no conflicts of interest in this work.

* Corresponding author. Department of Ophthalmology, Columbia University, 160 Fort Washington Avenue, Room 513, New York, NY 10032, USA.
E-mail addresses: sh2@columbia.edu, pde6gamma@gmail.com (S.H. Tsang).

http://dx.doi.org/10.1016/j.tjio.2015.06.002
2211-5056/© 2015, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights reserved.
2. Dark-adapted rod metabolism and the Warburg effect

The anabolic state of light-adapted rods is similar to the Warburg effect seen in cancer cells and stem cells, in which aerobic glycolysis is the exclusive catabolic process used to produce massive amounts of biomolecules for cell growth and division. Conversely, dark-adapted rods exhibit glycolysis as well as oxidative phosphorylation, which, similar to conventional neuronal metabolism, consumes large amounts of glucose and O2. Much of the understanding of the Warburg effect can potentially be applied to rod photoreceptors in light adaptation. The shift from oxidative phosphorylation to glycolysis allows for the production of two NADPH molecules per glucose molecule via the pentose phosphate pathway, which fuels the anabolic processes of the cell, and synthesis of amino acids, nucleic acids, lipids, and carbohydrates.

3. Cellular control of metabolism via hypoxia inducible factor 1 and SIRT6

Recently, new details of the molecular basis for the switch from aerobic respiration to aerobic glycolysis have been uncovered. It has long been known that a state of hypoxia or low nutrients induces cells to use glycolysis alone, rather than continuing catabolism through the tricarboxylic acid (TCA) cycle and oxidative phosphorylation. This switch to glycolysis is eponymously referred to as the “Pasteur effect.” Conversely, dark-adapted rods exhibit glycolysis as well as oxidative phosphorylation, which, similar to conventional neuronal metabolism, consumes large amounts of glucose and O2. Much of the understanding of the Warburg effect can potentially be applied to rod photoreceptors in light adaptation. The shift from oxidative phosphorylation to glycolysis allows for the production of two NADPH molecules per glucose molecule via the pentose phosphate pathway, which fuels the anabolic processes of the cell, and synthesis of amino acids, nucleic acids, lipids, and carbohydrates.

4. Rod energy demand drives retinal degenerative diseases

The high energy cost and O2 demand of dark-adapted rod cells are the bases for a recently developed theory for the mechanism of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinopathy of prematurity. During dark adaptation, partial pressure of oxygen nears zero at the ellipsoid zone where the rod mitochondria reside, which was shown in cats, monkeys, and rats. In low-oxygen settings, such as at a high elevation, and in diseases such as polycythemia vera and partial carotid occlusion, loss of dark adaptation is one of the first symptoms to manifest, indicating the high sensitivity of rods to hypoxic insult. Because rods operate in a near hypoxic state, any reduction in the oxygenation of the retina causes release of hypoxic factors, notably vascular endothelial growth factor (VEGF), which leads to neovascularization of either the choroidal (in AMD) or the retinal (in retinopathy of prematurity and DR) vasculature.

5. Rod metabolism in AMD

Early pathological changes observed in AMD are thickening of Bruch’s membrane and deposition of subretinal drusen. These
lead to a decrease in diffusion capacity of O₂ from the choriocapillaris to the retinal pigment epithelium (RPE), causing ischemia in the retina. In early disease stages, a manifestation of the ischemic injury is that dark adaptation is reduced compared with healthy age-controlled adults. This finding suggests that in AMD, rod function is actually impaired before macular degeneration occurs and before cone function is lost. The histological evidence that rods are lost in the parfoveal region of the retina where they are in the highest density and O₂ consumption is greatest also supports the theory that hypoxic/ischemic consumption causes degeneration of the macula. Subsequent cone photoreceptor death is generally accepted to be caused by rod death, with a rod-derived cone viability factor thought to play a prominent role in this process. The RPE releases VEGF normally to sustain the choriocapillaris, and without it, the choriocapillaris atrophies in normal aging. In “wet” AMD, usually the late-stage form of the disease, there is substantial neovascularization and subsequent capillary leakage, as opposed to in “dry” AMD, in which RPE atrophy predominates. Anti-VEGF therapies were successful taking advantage of this mechanism to suppress neovascularization in wet AMD.

In addition, in patients treated for DR with panretinal photocoagulation, the development of wet and dry AMD was shown to have reduced compared with patients with DR without panretinal photocoagulation treatment. This may be due to the dramatic decrease in the number of rods, lowering the burden of oxygenating the retina. A novel approach to treating AMD, which combats the high energy consumption by rods in darkness, is light therapy, in which patients are exposed to constant low levels of light. This has produced promising results in an early-stage AMD clinical trial.

6. Rod metabolism in DR

Similarly to AMD, it has been well established that the clinical development of DR begins with a decade-long pre-nonproliferative phase, followed by a nonproliferative phase that continues or becomes proliferative in the end-stage disease. The molecular pathophysiology is under constant debate; however, the importance of elevated glucose levels to initiate the disease and VEGF release to cause neovascularization is largely accepted in the field. Hyperglycemia has been shown to induce vascular changes in early and late stages of DR through retinal capillary damage from pericyte loss and possible alterations in retinal blood vessel diameter, retinal oxygenation, and retinal blood flow. Prolonged elevation of glucose level and advanced glycation products have been shown separately to increase VEGF release in RPE. Arden and others have advocated that VEGF release induced by elevated glucose levels and hypoxia is caused by the high energy demand of rod photoreceptors in dark adaptation. In support of their hypothesis, Arden and colleagues showed that patients with concurrent diabetes and retinitis pigmentosa (RP) do not develop DR, which, according to them, is due to a decrease in energy demand as a result of loss of rod photoreceptors. Arden and colleagues have also proposed light therapy for treatment of DR, which showed benefit in early disease stages. Other methods to lower energy demand from rod photoreceptors need to be explored to validate the hypothesis that rod energy consumption drives DR.

7. Rod metabolism in RP

The pathophysiological basis of photoreceptor loss in RP can also be due to excessive energy demand from being in a state that mimics dark adaptation or “equivalent darkness.” Rhodopsin is the most commonly mutated gene responsible for the disease, and mutation of rhodopsin and other phototransduction genes such as the phosphodiesterase (PDE) subunits causes impairment of phototransduction. Mutations of PDE6 that reduce enzyme activity have been shown to cause a disease state in mice that mimics RP and similar diseases, which may be rescued by the introduction of a wild-type copy of the gene via gene therapy. This leads to increased opening of the CNG channel and increased oxidative phosphorylation by rod photoreceptors in a state that mimics dark adaptation. Oxidative phosphorylation creates reactive oxygen species that may cause autophagy or apoptosis. In addition, one of the earliest histopathological signs of disease is shortening of the outer segments. As described above, light-induced outer segment turnover is one of the most important anabolic functions of rod cells, and if the cells are primarily using oxidative phosphorylation, they may not have adequate energy directed for rebuilding the outer segments. Many structural genes, ciliopathy genes, and protein trafficking genes known to be genetically responsible for RP likely contribute to the disease by also preventing adequate outer segment renewal. RP exhibits a characteristic pattern of rod loss beginning at the midperiphery of the retina where rod density is high, and occasionally a bull’s-eye pattern of rod loss is formed in the parafoveal region of highest rod density. This predication for atrophy in areas of high rod density further supports the notion that a rod process gone awry causes the disease, and we believe that rod cells succumb to the mutations that cause increased energy demand or other insults to the ability to renew outer segments. Treating RP with an agent that maintains rods in a state that mimics light adaptation, in which only glycolysis is used without oxidative phosphorylation, may allow for increased preservation of rod cells’ ability to maintain outer segments and survive. In preclinical studies using mice as models of RP, increased mammalian target of rapamycin (mTOR) signaling has been shown to prolong photoreceptor survival. The mTOR signaling is also known to induce aerobic glycolysis, which may explain why increased mTOR signaling is protective for RP.

8. Conclusion

The above evidence gives credence to the theory that overburdening rod metabolism causes several retinopathies. More studies must be performed to further understand the mechanism by which oxidative phosphorylation leads to rod death, and to determine the treatment options based on this knowledge. Whether this theory can be applied to other retinal degenerative diseases is currently being explored.

References

1. Okawa H, Sampath AP, Laughlin SB, Fain GL. ATP consumption by mammalian rod photoreceptors in darkness and in light. Curr Biol. 2008;18:1917–1921.
2. Nakanishi S. Second-order neurones and receptor mechanisms in visual- and olfactory-information processing. Trends Neurosci. 1995;18:359–364.
3. Yau KW, Hardie RC. Phototransduction motifs and variations. Cell. 2009 Oct 16;139(2):246–264. http://dx.doi.org/10.1016/j.cell.2009.09.029.
4. Fain GL, Hardie R, Laughlin SB. Phototransduction and the evolution of photoreceptors. Curr Biol. 2010;20:R114–R124.
5. Tsang SH, Woodruff ML, Chen CK, et al. GAP-independent termination of photoreceptor light response by excess gamma subunit of the cGMP-phosphodiesterase. Cell. 2006;25:4472–4480.
6. Tsang SH, Woodruff ML, Janisch KM, Cilluffo MC, Farber DB, Fain GL. Removal of phosphorylation sites of gamma subunit of phosphodiesterase 6 alters rod light response. J Physiol. 2007;579(Pt 2):303–312.
7. Woodruff ML, Janisch KM, Peshenko IV, Dizhoo AM, Tsang SH, Fain GL. Modulation of phosphodiesterase6 turnover during background illumination in mouse rod photoreceptors. J Neurosci. 2008;28:2064–2074.
8. Tsang S, Woodruff M, Lin C, et al. Effect of the ILE86TER mutation in the gamma subunit of cGMP phosphodiesterase (PDE6) on rod photoreceptor signalling. Cell Signal. 2012;24:181–188.
9. Tsang SH, Woodruff ML, Jun L, et al. Transgenic mice carrying the H258N mutation in the gene encoding the beta-subunit of phosphodiesterase-6.
Havelius U, Berglund S, Falke P, Hindfelt B, Krakau TI. Impaired dark adaptation in symptomatic carotid artery disease. Neurology 2010;74:1359–66.

Leviard T, Sahel JA. Rod-derived cone viability factor for treating bleeding diseases: from clinic to redox signaling. Sci Transl Med 2010;2:26ps16.

Wittmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1–29.

Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 2014;98:1144–1167.

Zylbermann R, Landau D, Rozenman Y, Abrahami S, Pollack A. Exudative age-related macular degeneration in patients with diabetic retinopathy and its relation to retinal laser photococouagulation. Eye (London, England). 1997;11(Pt 6):872–875.

Arden GB, Gunduz MK, Kurtenbach A, et al. A preliminary trial to determine whether prevention of dark adaptation affects the course of early diabetic retinopathy. Eye (London, England). 2010;24:1149–1155.

Guilla TA, Amador AG, Zimman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003;26:2653–2664.

Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615–1625.

Pourmarcj A, Rungger-Brandle E, Riva CE, Hardinson SH, Stefannson E. Regulation of retinal blood flow in health and disease. Prog Retin Eye Res 2008;27:284–330.

Sone H, Kawakami Y, Okuda Y, et al. Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glycemic dereplication in human retinal pigmented epithelial cells. Biochem Biophys Res Comm 1996;221:193–198.

Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increases retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101:1219–1224.

Arden GB, Wolf JE, Tsang Y. Does dark adaptation exacerbate diabetic retinopathy? Evidence and a linking hypothesis. Vision Res. 1998;38:1723–1729.

Arden GB, Svaprasad S. Hypoxia and oxidative stress in the causation of diabetic retinopathy. Curr Diabetes Rev 2011;7:291–304.

Arden GB. The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment. Br J Ophthalmol. 2001;85:366–370.

Hartong DT, Berlin EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368:1795–1809.

Davis RJ, Tsoi J, Janisch KM, et al. Functional rescue of degenerating photoreceptors in mice homozygous for a hypomorphic cGMP phosphodiesterase 6 β allele (Pde6bH620Q). Invest Ophthalmol Vis Sci. 2008;49:5067–5076.

Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 2007;26:1749–1760.

Circu ML, Aw TY, Reactive oxygen species, cellular redox systems, and apoptosis. Free Rad Biol Med. 2010;48:749–762.

Fariss RN, Li Z-Y, Milam AH. Abnormalities in rod photoreceptors, amacrine cells, and horizontal cells in human retinas with retinitis pigmentosa. Am J Ophthalmol. 2000;129:215–223.

Curcio CA, Sloan KR, Kalina RE, Hendrickson AE. Human photoreceptor topography. J Comp Neurol. 1990;292:497–523.

Tsang SH, Chan L, Tsai YT, et al. Silencing of tuberin enhances photoreceptor survival and function in a preclinical model of retinobin pigmentation (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2014;112:103–115.

Punzo C, Kornacker K, Cepko CL. Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. Nat Neurosci. 2009;12:44–52.

Sun Q, Chen X, Ma J, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A. 2011;108:4129–4134.

36. Owsley C, Jackson GR, Cideciyan AV, et al. Psychophysical evidence for rod vulnerability in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2000;41:267–273.

37. Curcio CA. Photoreceptor topography in ageing and age-related maculopathy. Eye (London, England). 2001;15(Pt 6):381–383.

38. Leveillard T, Sahel JA. Rod-derived cone viability factor for treating bleeding diseases: from clinic to redox signaling. Sci Transl Med 2010;2, 26ps16.

39. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1–29.

40. Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 2014;98:1144–1167.

41. Zylbermann R, Landau D, Rozenman Y, Abrahami S, Pollack A. Exudative age-related macular degeneration in patients with diabetic retinopathy and its relation to retinal laser photococouagulation. Eye (London, England). 1997;11(Pt 6):872–875.

42. Arden GB, Gunduz MK, Kurtenbach A, et al. A preliminary trial to determine whether prevention of dark adaptation affects the course of early diabetic retinopathy. Eye (London, England). 2010;24:1149–1155.